Psoriasis News and Research

Latest Psoriasis News and Research

Nearly half a million dollars given to physicians working to cure psoriatic diseases

Nearly half a million dollars given to physicians working to cure psoriatic diseases

3 Jul 2013
Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

3 Jul 2013
Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

2 Jul 2013
Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

28 Jun 2013
Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

Janssen, Johnson & Johnson Innovation establish IBD research alliance with Mount Sinai

27 Jun 2013
Karo Bio extends research collaboration with Pfizer on RORgamma modulators

Karo Bio extends research collaboration with Pfizer on RORgamma modulators

26 Jun 2013
Researchers discover a rational source of pain in skin of patients with fibromyalgia

Researchers discover a rational source of pain in skin of patients with fibromyalgia

19 Jun 2013
Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

15 Jun 2013
Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

14 Jun 2013
Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

13 Jun 2013
Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

13 Jun 2013
New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

13 Jun 2013
Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

12 Jun 2013
Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

5 Jun 2013
Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

3 Jun 2013
XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

XenoPort's Arbaclofen placarbil fails to meet co-primary endpoints in Phase 3 clinical trial

20 May 2013
Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

Galapagos, AbbVie announce extension of GLPG0634 clinical development collaboration

17 May 2013
Researchers explain why cost of care higher for men with severe psoriasis

Researchers explain why cost of care higher for men with severe psoriasis

16 May 2013
Implications for manipulating immune response for some inflammatory disorders

Implications for manipulating immune response for some inflammatory disorders

14 May 2013
Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

13 May 2013

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback